Table 2. Inflammatory markers and biochemical characteristics of type 2 diabetic elderly patients.

	All subjects	depressive syndrome	depressive syndrome and MCI	MCI	Controls	Difference (p<0.001)
Nr of patients	276	57	25	62	132
CRP (mg/L)	5.08±2.8	5.52±2.5	9.77±3.3	6.72±1.7	3.24±1.3	a, b, c, d, e, f
IL-6 (pg/ml)	4.68±2.5	5.22±1.7	8.39±1.9	6.87±1.2	2.71±1.2	a, b, c, e, f
TNF-α (pg/ml)	5.33±2.6	5.51±2.1	9.02±2.4	7.3±1.8	3.63±1.5	a, b, c, d, e, f
HbA1c (%)	7.24±0.68	7.06±0.6	8.02 ± 0.68	7.62±0.69	7±0.5	a, b, e, f
CHOL (mmol/L)	10.3±2.18	11.96±2.12	10.75± 2.1	10.13±2.2	9.58±1.76	b, c, e
LDL (mmol/L)	6.06±1.67	7.1±1.8	6.54 ± 1.89	5.79±1.49	5.64±1.5	b, c, e
TG (mmol/L)	9.65±2.23	9.16±1.98	11.33±2.63	10.29±2.66	9.24±1.79	a, b, e, f
HDL (mmol/L)	2.5± 0.51	2.69±0.37	2.15 ± 0.45	2.36±0.64	2.66±0.44	a, b, e, f

a- comparing: depressive syndrome—MCI and depressive syndrome;

b- comparing: depressive syndrome—MCI

c- comparing: depressive syndrome—controls

d- comparing: MCI and depressive syndrome—MCI

e- comparing: MCI and depressive syndrome-controls

f- comparing: MCI—controls

DM2—diabetes type 2, OAD- oral anti-diabetic drug, CVD—cardiovascular disease, HA- hypertension, BMI—body mass index, MoCA—Montreal Cognitive Assessment, GDS—Geriatric Depression Scale

The ANOVA test followed by post-hoc test was used to test for significant differences